For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
As a drug improving energy metabolism, deproteinized calf blood extract has received wide attention due to its efficacy in nervous system. Currently, it is mainly used to treat brain disease, nervous system disease, vascular disease, ulcer, burn, radiation injury and eye disease.
Developed by Jaeger KH with membrane filtering technology, deproteinized calf blood extract is the deproteinized blood extract of new-born calf with a relative molecular mass of less than 6000 dalton. Since the 1960s, deproteinized calf blood extract has been marketed all over the world.
Recently, nervous system drug has reported a stable growth. Among the TOP500 drugs in the seven big markets, nervous system drug reported a sales value of USD 43.286 billion with a year-on-year growth of 3% in 2013. Brain system drug, in particular, has undergone a downturn in global market. However, as people become increasingly aware of the pathogenesis and clinical pharmacology of neurologic diseases, the market of neurologic drug has grown fast in China. As a leading neurologic drug, deproteinized calf blood extract has reported a large sales in China. By the end of Aug.2015, there are 18 manufacturers of deproteinized calf blood extract and deproteinized calf blood extract injection, 3 manufactures of deproteinized calf blood extract ophthalmic gel and 1 manufacturer of deproteinized calf blood extract capsule.
According to CRI’s market survey, the sales value of deproteinized calf blood extract in sample hospitals reached about CNY 1.2 billion and CAGR during the period of 2005-2014 surpassed 30%. Jinzhou Ahon Pharmaceutical Co., Ltd, Heilongjiang Jiangshi Pharmaceutical Co., Ltd, Harbin Sanctity Pharmaceutical Co., Ltd, Jilin Connell Pharmaceutical Co., Ltd and Wuhan Humanwell Pharmaceutical Co., Ltd occupy the market, among which Jinzhou Ahon Pharmaceutical Co., Ltd had the largest market share of about 71% for sales value in 2014.
The market size of deproteinized calf blood extract in China is expected to keep growing in next few years.
Readers can get at least the following information through this report:
- market size of deproteinized calf blood extract in China
- competitive landscape of deproteinized calf blood extract market in China
- price of deproteinized calf blood extract made by different enterprises in China
- market outlook of deproteinized calf blood extract in China
The author suggests the following groups of people purchase this report:
- drug makers
- investors/research institutions interested in Chinese medicine market
- any interest in Chinese medicine market, please contact CRI for customized survey service
Companies Mentioned
Jinzhou Ahon Pharmaceutical Co., Ltd; Harbin Sanctity Pharmaceutical Co., Ltd; Heilongjiang Jiangshi Pharmaceutical Co., Ltd; Jilin Connell Pharmaceutical Co., Ltd; Wuhan Humanwell Pharmaceutical Co., Ltd; Shenyang Sinqi Pharmaceutical Co., Ltd